AFFILIATIONS
1 Virginia Commonwealth University, Richmond, United States
ABSTRACT
Background: Consolidation with autologous hematopoietic cell transplantation (auto-HCT) for peripheral T-cell lymphomas (PTCL) remains controversial. Prior studies reported mixed results, and interpretation was limited because transplant cohorts were younger and had fewer comorbidities than observation-only cohorts. This study analyzes the impact of auto-HCT versus observation after initial chemotherapy on overall mortality and time to next treatment in PTCL.
Methods: This retrospective cohort study using the TriNetx Research Network analyzed adults 18 years or older with PTCL-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), or ALK-negative anaplastic large cell lymphoma (ALK-negative ALCL) from 2005 to 2025. Cohort 1 (N=479) had auto-HCT within a year of diagnosis after one line of induction chemotherapy. Allogeneic HCT recipients were excluded. Cohort 2 (N=21,104) had chemotherapy only and no autologous or allogeneic HCT. Propensity score matching (1:1) balanced age, gender, race, and relevant comorbidities in the two cohorts. The analysis was conducted within the TriNetX platform using built-in survival and risk assessment tools.
Results: After propensity score matching, baseline characteristics in cohort 1 (N=239) and cohort 2 (N=239) were balanced for age (median 60 [IQR, 16] vs. 59 [IQR, 23] years, p = 0.06); gender (male 55.2% vs 51.5%, p = 0.4); race (White 69% vs 66.9%, p=0.6; Black 7.9% vs 10%, p = 0.4); Hispanic/Latino ethnicity 6.3% vs 6.3%, P=0.5; diabetes (21% vs. 19%, p = 0.6); ischemic heart disease (18% vs. 16%, p=0.2); obesity (19% vs. 15%, p =0.2). Median follow-up was 2 years (IQR, 0.9) for cohort 1 and 2 years (IQR, 1.4) for cohort 2.
Kaplan-Meier survival analysis found that the auto-HCT cohort had a significantly greater 2-year survival probability than the observation cohort (82.0% vs 73.0%; Cox HR = 0.60, 95% CI 0.40 to 0.90, log-rank p = 0.02). Consolidation with auto-HCT also significantly prolonged the time to next treatment, yielding a 2-year treatment-free probability of 91.0% versus 74.0% (log-rank p < 0.001). In Cox regression analysis, auto-HCT reduced the need for subsequent therapy by 72% (HR = 0.28, 95% CI 0.17 to 0.48, p < 0.001), satisfying the proportional hazards assumption (p = 0.226).
Multivariable Cox analysis identified age, male gender, stage IV disease, diabetes, and ischemic heart disease as independent predictors of higher mortality (all p < 0.001). Whereas White race (p < 0.001) and Hispanic/Latino ethnicity (p = 0.004) were independently associated with superior overall survival. Black race; specific lymphoma histology PTCL-NOS, AITL or ALK-negative ALCL; obesity class 3 BMI 40 kg/m2 or higher, obesity class 2 BMI 35 -39.9 kg/m2, and obesity class 1 BMI 30-34.99 kg/m2 showed no significant associations with overall survival.
Conclusion: In a real-world cohort of PTCL-NOS, AITL, and ALK-negative ALCL balanced by age, gender, race, and comorbidities, auto-HCT consolidation is associated with significantly reduced overall mortality and the need for next-line therapy.
DISCLOSURES
Baldeep Wirk, MD: No relevant conflicts of interest to declare.